The firm attributed the increase in part to life sciences and diagnostics revenue that was better than expected.
The company is the first commercial lab in the US to agree to implement the system, which it will begin using in the first quarter of the year.
The test detects Borrelia bacteria directly from skin interstitial fluid samples from people with signs of tick bites or erythema migrans.
The approach uses an iteration of the SHERLOCK technology exclusively licensed to OraSure Technologies' subsidiary, Sherlock Biosciences.
Meridian Bioscience subsidiary Magellan Diagnostics was previously ordered to pay $42 million for selling the tests.
The firm attributed the increase in part to life sciences and diagnostics revenue that was better than expected.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results